CN1044559C - 抗白血病、肝癌、淋巴瘤注射液 - Google Patents

抗白血病、肝癌、淋巴瘤注射液 Download PDF

Info

Publication number
CN1044559C
CN1044559C CN95108768A CN95108768A CN1044559C CN 1044559 C CN1044559 C CN 1044559C CN 95108768 A CN95108768 A CN 95108768A CN 95108768 A CN95108768 A CN 95108768A CN 1044559 C CN1044559 C CN 1044559C
Authority
CN
China
Prior art keywords
injection
leukemia
sodium chloride
water
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN95108768A
Other languages
English (en)
Other versions
CN1121807A (zh
Inventor
张亭栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital Of Harbin Medical University
Original Assignee
First Affiliated Hospital Of Harbin Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5076886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1044559(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by First Affiliated Hospital Of Harbin Medical University filed Critical First Affiliated Hospital Of Harbin Medical University
Priority to CN95108768A priority Critical patent/CN1044559C/zh
Publication of CN1121807A publication Critical patent/CN1121807A/zh
Priority to US08/702,011 priority patent/US6720011B1/en
Application granted granted Critical
Publication of CN1044559C publication Critical patent/CN1044559C/zh
Priority to US10/715,166 priority patent/US20040101573A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种抗白血病、肝癌、淋巴瘤注射液。已有技术对于白血病等完全缓解率低。本产品组成包括：注射用水，其特征是：所述的注射用水中溶有三氧化二砷1-10克、氯化钠8克，共计1000毫升。使用本品治疗后完全缓解率高达84%，长期存活者已达21年之久，本发明还对于抑制DNA、RNA的合成、抑制及其克隆增殖能力的丧失具有较强的作用。本发明对白血病的细胞膜的破坏也有很强的作用。本产品适用于治疗白血病、肝癌、淋巴瘤。

Description

抗白血病、肝癌、淋巴瘤注射液
本发明涉及一种含砷的医用配制品，具体说是一种抗白血病、肝癌、淋巴瘤注射液。
本发明所针对的癌症是当今危及人类生命的恶性疾病，一但发病其自然生存期为3-6个月。其中尤其白血病，治疗难度大，死亡率高，长期存活十分困难。目前治疗主要是化疗为主，国外儿童完全缓解率(CR)75％，成人为70-80％,5年无病生存率35-40％。采用骨髓移植方法治疗的4年生存率为59％。国内的治疗水平为，急性白血病完全缓解率为60-70％,5年无病生存率不足10％，应用维甲酸治疗完全缓解率(CR)为85％，为世界先进水平，但易复发，而且复发后再用此药治疗也不可能再次收到疗效，并且副作用强，病人常因此不能耐受而停药。
在本发明完成过程中，曾将另一阶段性配方交本申请人内部临床部门检验，使用当时的配方治疗白血病达到的临床结果是：完全缓接率为61.11％。
本发明的目的在于提供一种用于静脉滴注的抗白血病、肝癌、淋巴瘤注射液，治疗急性白血病、肝癌、淋巴瘤，治疗效果佳，毒副作用很小。
本发明的目的是这样实现的：
一种抗白血病、肝癌、淋巴瘤注射液，其组成包括：注射用水所述的注射用水中溶有三氧化二砷1-10克、氯化钠8克，共计1000毫升。
将以上有效成份经煮沸过滤灭菌制成本产品，配制的过程见实施例。
本发明的优点在于：
1．本发明对于急性早幼粒细胞性白血病治疗缓解率高，长期存活率大，完全缓解率(CR)为84％。长期存活者已达21年之久。
2．实验证明本发明对于抑制DNA、RNA的合成、抑制及其克隆增殖能力的丧失具有较强的作用。对白血病的细胞膜破坏也有很强的作用。
3．体内、体外实验证实有显著的杀伤白血病细胞作用，并有诱导白血病细胞向正常细胞分化作用。
4．可促进骨髓造血功能的恢复，对骨髓造血功能无抑制作用，可很快改善贫血状态。
5．可通过血脑屏障，这是多种化疗药品所不及的。因此，很少合并脑膜白血病
6．对巨核细胞有促进增生作用。使血小板迅速恢复，因而很少发生凝血机制障碍而出血。
7．通过电镜观察，超微结构病理细胞确向正常细胞转化。
实施例1：一种抗白血病、肝癌、淋巴瘤注射液，其组成包括：注射液共1000毫升，其特征是：所述的注射用水中溶有三氧化二砷1-10克、氯化钠8克，经煮沸、过滤、灭菌而成。
应用本发明的110名急性早幼粒细胞性白血病患者的临床统计，其中男性69例、女性41例，年龄13-65岁。
治疗患者入院时有不同程度出血的91例，有不同部位感染的95例，血象化验红蛋白≤100克/升者101例，白细胞≥10×10\L者82例，血小板≤100×10\L者106例，骨髓增生活跃者105例，早幼粒细胞性白血病细胞≥60％者90例。
经2-4周治疗后：
1．在幼稚细胞减少的同时白细胞总数随之由质变到量变。
2．血小板上升，血红蛋白上升，同时可见幼红细胞。
3．骨髓可见异常原早粒细胞质变化的同时总数下降，红系增生转活跃。
4．成熟巨红细胞增多，临床症状明显好转。
5．其结果是：完全缓解率(CR)84％，部分缓解率(PR)3.6％。20年来对24例完全缓解的病例进行了长期的随访，其中5例在完全缓解后1-4年死于严重感染及脑出血。另外19例均存活10年以上，其中有17例目前仍健在，最长者已经存活21年。
实施例2：实施例1所述的产品的置备，取三氧化二砷10克、氯化钠8克、注射用水1000毫升，先将1000毫升注射用水加热煮沸，加入三氧化二砷10克继续煮沸30分钟，当完全溶解后加入8克氯化钠，同时补加入注射用水至1000毫升，用G3垂溶玻璃漏斗过滤后，灌注、溶取、灭菌即制成。
使用剂量：成人取本品10毫升加入到50倍剂量的10％葡萄糖中，四周一疗程。儿童按年龄递减。

Claims (1)

1．一种抗白血病、肝癌、淋巴瘤注射液，其组成包括：注射用水，其特征是：所述的注射用水中溶有三氧化二砷1-10克、氯化钠8克，共计1000毫升。
CN95108768A 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液 Expired - Lifetime CN1044559C (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN95108768A CN1044559C (zh) 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液
US08/702,011 US6720011B1 (en) 1995-08-23 1996-08-23 Injectable composition for cancer treatment
US10/715,166 US20040101573A1 (en) 1995-08-23 2003-11-17 Injectable composition for cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN95108768A CN1044559C (zh) 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液

Publications (2)

Publication Number Publication Date
CN1121807A CN1121807A (zh) 1996-05-08
CN1044559C true CN1044559C (zh) 1999-08-11

Family

ID=5076886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95108768A Expired - Lifetime CN1044559C (zh) 1995-08-23 1995-08-23 抗白血病、肝癌、淋巴瘤注射液

Country Status (2)

Country Link
US (2) US6720011B1 (zh)
CN (1) CN1044559C (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1374875A3 (en) 1997-10-15 2004-01-07 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome
JP2001522799A (ja) * 1997-11-10 2001-11-20 メモリアル スローン−ケタリング キャンサー センター 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR100272835B1 (ko) * 1998-05-08 2000-11-15 배일주 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물
EP1732527A2 (en) * 2004-03-17 2006-12-20 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
WO2014045083A1 (en) 2012-09-20 2014-03-27 Bendale Yogesh Narayan Process for bio synthesis of nano arsenic trioxide and its use in treatment of diseases including cancers
CN103393719B (zh) * 2013-08-07 2014-07-23 骆红宇 一种三氧化二砷口服液的生产方法
MX2017009913A (es) 2015-02-01 2018-08-15 Orsenix Holdings Bv Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes.
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US9700580B1 (en) 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
CN107982278A (zh) * 2017-12-15 2018-05-04 哈尔滨医科大学 一种用于治疗血管生成介导疾病的药物及应用
GB201800736D0 (en) 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO930510A1 (it) * 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
JP2001522799A (ja) * 1997-11-10 2001-11-20 メモリアル スローン−ケタリング キャンサー センター 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
哈尔滨医科大学学报1995年第29卷第3期 1995.6.25 张鹏，王树叶，胡龙虎，"‘713’治疗急性早幼粒细胞白血病117例临床观察及机制探讨" *

Also Published As

Publication number Publication date
CN1121807A (zh) 1996-05-08
US6720011B1 (en) 2004-04-13
US20040101573A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
CN1044559C (zh) 抗白血病、肝癌、淋巴瘤注射液
Whalley et al. Oxytocin and water intoxication
US4787883A (en) Extracorporal thermo-therapy device and method for curing diseases
WO1993004678A1 (en) Antimicrobial preservation of platelets and blood factors
US6361805B2 (en) Method of preparation and composition of a water soluble extract of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals
CN105380956B (zh) 一种治疗白血病的含艾德拉尼的药物组合物及应用
CN1087610C (zh) 香菇多糖注射液及其制备方法
CN111529549B (zh) 一种抗菌抗病毒的高化合价电解银离子溶液及其制备方法
CN102240261A (zh) 一种葡甘露聚糖注射液的制备方法及其医学用途
CN1468600A (zh) 多索茶碱葡萄糖注射液的制备方法
EP0778026A1 (en) Remedy for endotoxinemia and multiple organ failure induced thereby
KR20020031404A (ko) 혈장 대체 조성물
WO2000021518A1 (en) Drug preparation 'histochrome' for treating ocular conditions
CN101019949B (zh) 清开灵大输液制剂及其制备方法
WO1993004731A1 (en) Iodine-iodide treatment of red blood cells
WO1994000011A1 (en) Starch-iodine-peroxide preservation of blood, tissues and biological fluids
CN111450175B (zh) 治疗化疗后胃肠道反应的联合用药物或药盒产品及应用
RO137645A0 (ro) Supliment alimentar branca ursului/argint/chitosan
CN1194831A (zh) 利巴韦林大输液系列制剂
Strauss et al. Selecting the optimal dose of low‐molecular‐weight hydroxyethyl starch (Pentastarch) for granulocyte collection
RU2053787C1 (ru) Способ получения лекарственного средства из чеснока
SU862418A1 (ru) Кровезаменитель
Stevenson et al. A fatal case of agranulocytosis due to thenalidine tartrate complicated by acute renal failure and mycelial abscesses of brain
Islam et al. Naphthalene Induced Hemolysis With Acute Kidney Injury in a g6pd Deficient Boy
WO1994000161A1 (en) Povidone hydrogen peroxide preservation of blood, tissues and biological fluids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: HARBIN FIRST HOSPITAL

Document name: Invalidation case notification

CX01 Expiry of patent term

Expiration termination date: 20150823

Granted publication date: 19990811

EXPY Termination of patent right or utility model